Sunshine Biopharma vs Verrica Pharmaceuticals
Sunshine Biopharma and Verrica Pharmaceuticals are similar in size: $36.3m and $35.6m of revenue in their latest fiscal years. Verrica Pharmaceuticals grew faster (370.2% against 4.1%). Sunshine Biopharma kept more of each dollar of sales as profit: a net margin of -16.5% against -50.3%. Sunshine Biopharma carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Sunshine BiopharmaSBFM, 2025 | Verrica PharmaceuticalsVRCA, 2025 |
|---|---|---|
| Revenue | $36.3m | $35.6m |
| Revenue growth | 4.1% | 370.2% |
| Net income | −$6.0m | −$17.9m |
| Operating margin | -17.2% | -34.2% |
| Net margin | -16.5% | -50.3% |
| Return on equity | -25.7% | — |
| Free cash flow | −$5.5m | −$17.6m |
| Cash | $9.1m | $30.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 50 | 76 |
| Market value | $6.5m | $57.5m |
| Price vs our value range | — | — |
| Moat score | 15 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 12 buys, 0 sales |